⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
Phase IAndrogen Modulator

Compound 61542

Formula Pending

Molecular Mass
N/A
CAS Registry
AUTO-061542
Risk Class
MODERATE
Last Audit
Apr 1, 2108

Research Abstract

Androgen Modulator candidate engineered for endocrine support initiatives with automated dossier coverage.

Compound 61542 is a androgen modulator asset inside androgen modulator innovation track initiatives, optimized for endocrine support and performance longevity.

The dossier currently sits in phase i with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.

Supply records cite CAS AUTO-061542 with updates logged 2108-04-01.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Primary Vectors

Endocrine supportPerformance longevity

Nomenclature

CX-61542Androgen Modulator Program 61542

Reference Material

  1. [1] Anubis Compound Registry • CAS AUTO-061542
  2. [2] Operations Pulse • Androgen Modulator innovation track
  3. [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61542